Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial

Publication date: Available online 18 February 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Tone S Løvvik, Sven M Carlsen, Øyvind Salvesen, Berglind Steffensen, Marie Bixo, Francisco Gómez-Real, Marianne Lønnebotn, Kristin V Hestvold, Renata Zabielska, Angelica L Hirschberg, Anastasia Trouva, Solveig Thorarinsdottir, Sissel Hjelle, Ann Hilde Berg, Frida Andræ, Inger S Poromaa, Johanna Mohlin, Maria Underdal, Eszter VankySummaryBackgroundWomen with polycystic ovary syndrome (PCOS) have an increased risk of pregnancy complications. Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group. The aim of this third randomised trial (PregMet2) was to test the hypothesis that metformin prevents late miscarriage and preterm birth in women with PCOS.MethodsPregMet2 was a randomised, placebo-controlled, double-blind, multicentre trial done at 14 hospitals in Norway, Sweden, and Iceland. Singleton pregnant women with PCOS aged 18–45 years were eligible for inclusion. After receiving information about the study at their first antenatal visit or from the internet, women signed up individually to participate in the study. Participants were randomly assigned (1:1) to receive metformin or placebo by computer-generated random numbers. Randomisation was in blocks of ten for each country and centre; the first bl...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research